Cytovance Biologics, a US-based contract manufacturing organisation specialising in mammalian and microbial biologics, has welcomed Mark Ambrose as Senior Director of Quality Systems and Compliance and Anne Garstka as Director of Commercial Compliance.
Ambrose joins the Oklahoma City-based company with 20 years of experience. Prior to Cytovance, he was Vice President of Quality at Nuron Biotech. In a limited capacity, he also served as acting Head of Regulatory Affairs.
Before Nuron Biotech, Ambrose was at Wyeth Biotech, now Pfizer, as both a Quality Operations Product Leader and Director of Sustainable Compliance.
Garstka joins Cytovance Biologics with more than 15 years of quality and compliance management experience. Prior to Cytovance, she was Director of Quality Assurance and Compliance for Neos Therapeutics.
Before Neos Therapeutics, Garstka was employed by Celgene Celluar Therapeutics as a Quality Assurance Manager. She has also held various positions with Celgene Corporation, Amgen, Watson Pharmaceuticals, and SP Pharmaceuticals in Quality roles.
